Podcasts about Colchicine

Send us Fan MailIn this podcast I talk about the recently published STIMULATE-ICP trial. This is a UK based clinical trial in which 4 drugs were randomly allocated to patients with Long Covid. The patients were assessed for fatigue using the accredited Fatigue Assessment Scale prior to treatment, at 12 weeks of treatment, and then after treatment had been discontinued 12 weeks later. Patients were selected randomly from NHS Long Covid Clinics around the UK. They were assigned to one of the four arms of the study which were as follows: Rivaroxaban; Colchicine; Loratadine and Famotidine combination; control 'no drug' arm. All four study arms continued to receive standard specialist care from their NHS Long COVID Service. The results are presented and discussed.I am Dr Tim Robinson, formerly a GP family doctor for 30 years, retired as planned at the start of the Covid pandemic. Since then I have specialised exclusively in Long Covid, over the last 6 years. Currently I am GP clinical lead for NHS Long Covid Services in South West England - Bristol, North Somerset and South Gloucestershire. I provide medical support for Hope for the Community CIC. I have research involvement as co-investigator in a study on breathlessness in Long Covid, University of Bristol UK. I also provide online patient recovery programmes, for both Long Covid and ME/CFS.Long Covid Doctor is an educational series for Long Covid sufferers; each talk covers the many aspects of Long Covid, the symptoms, causes, treatments, management and expected outcomes.Episodes are found on:Apple PodcastsSpotifyGoogle PodcastsYouTubeTranscripts of the individual episodes are available on YouTube as well as:www.LongCovidDoctor.comEpisodes are accessed on:TwitterFacebookInstagramLinked inDisclaimer: Long Covid Doctor is an educational series. Any advice, diagnosis, treatments mentioned should only be considered after discussion with your own GP or qualified professional health provider.Link for STIMULATE-ICP paper, The Lancet Infectious Diseases journal:SWEETMAN, JENNY  and Consortium, STIMULATE-ICP (2026) Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. Lancet Infectious Diseases. ISSN: 1474-4457https://doi.org/10.1016/S1473-3099(26)00242-2General resources for Long Covid:NICE Covid-19 rapid guideline:https://www.nice.org.uk/guidance/ng188/chapter/5-ManagementHow to manage post viral fatigue after Covid-19:https://www.rcot.co.uk/how-manage-post-viral-fatigue-after-covid-19-0

Commentary by Dr. Timothy Ka-chun UN.

Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo  Dr. Lisa Stamp  Dr. Michael Pillinger  Dr. Ted Mikuls  Moderator: Dr. Jack Cush

Send us Fan MailMary Yoder was a healthy 60 year old chiropractor, when suddenly one afternoon she fell horribly ill and in less than 48 hours she had passed away, when the pathologist found Colchicine in her system, a potent medication used to treat gout, which Mary did not suffer from, it quickly became apparent that Mary had not died from natural causes and despite not having any enemies at all, 3 people quickly became suspicious, and all for very different reasons.Support the showIf you're interested in receiving bonus episodes, early release dates,  an everything scary sticker and ‘thank you' as well as a shout out on our regular feed! Please join at  Patreon//everythingscarypod571

Dans cet épisode, vous trouverez un véritable kit pratique de la colchicine ! Quels sont les points essentiels à connaître en 2026 sur la colchicine ? Combien de temps faut-il poursuivre le traitement lors d'une crise ou en prophylaxie ? Quelles sont les principales interactions à connaître absolument pour sécuriser la prescription ?Le Pr Frédéric Lioté, rhumatologue à Paris, nous éclaire à ce sujet.Notre invité déclare ne pas avoir de lien d'intérêt en rapport avec le sujet traité.L'équipe :Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret, Dr Roba Ghossan.Animation : Marguerite de RodellecProduction : MedShake StudioSoutien institutionnel : Pfizer

In episode 620, Mike K and James bring back Danielle Perry, this time to talk about the evidence around the use of colchicine for secondary cardiovascular prevention. There are some large RCTs so we talk about all the numbers and as always put them into the proper context. To claim your CPD credits, click the link below and then select "Claim Credits Now".  BS Medicine Episode #620: Back on the stand: Colchicine for secondary cardiovascular prevention update - CFPCLearn

In episode 620, Mike K and James bring back Danielle Perry, this time to talk about the evidence around the use of colchicine for secondary cardiovascular prevention. There are some large RCTs so we talk about all the numbers and as always put them into the proper context. Show Notes Tools For Practice Back on […]

Would strontium help in the healing of lumbar fractures?  How about as a preventive?How valuable is the hs-CRP test?  Are there any drawbacks to eating canned fish?What are your thoughts on Arterosil for cardiovascular health?

The benefits of saunaThe Take Back Your Health TourA follow-up on milk thistle interactions with drugsWhat are your thoughts on low-dose saw palmetto for hair growth?Is monk fruit a safe sweetener to use?

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2 Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Aernoud Fiolet from Utrecht in the Netherlands. They discuss the imaging substudy of the LoDoCo2 trial, which tested colchicine in patients with chronic coronary syndromes. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/111/23/1156.long  

My guest is Dr. David Fajgenbaum, MD, professor of translational medicine and human genetics at the University of Pennsylvania. He explains how, unbeknownst to most doctors, many approved medications can successfully treat or even cure diseases other than the ones they are typically used to treat. He shares his story of escaping death from Castleman's disease by discovering a life-saving treatment using repurposed drugs that were approved for other purposes. Our conversation explores how researchers, physicians, and you—the general public—can explore novel treatments and cures to conditions the medical profession has deemed untreatable, including cancers. We also discuss the crucial role of mindset in battling diseases and the lesser-known use of compounds to promote health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Eight Sleep: https://eightsleep.com/huberman Rorra: https://rorra.com/huberman David: https://davidprotein.com/huberman Function: https://functionhealth.com/huberman Timestamps (0:00) David Fajgenbaum (4:06) Self-Agency in Healthcare; New Uses for Old Medicines (6:44) Other Uses of Aspirin & Viagra; Drug Development & Approved Use (8:53) Lidocaine & Breast Cancer; Pharmaceutical Companies & Incentives (11:36) Sponsors: Eight Sleep & Rorra (14:16) Pharmaceutical Companies, Patents & New Uses; Lithium (18:40) Tools: Finding Reliable Health Sources, Asking Questions & Disease Organizations; DADA2 Treatment (21:53) Medical Community & Connections; Integrated Medical Databases (24:36) Drug Repurposing, Thalidomide, Pembrolizumab (28:45) Medical Research Databases, Mapping Disease Connections (33:51) Every Cure Database & Programs, Bachmann-Bupp Syndrome; Colchicine & Heart Disease (37:57) Sponsors: AGZ by AG1 & David (40:41) David's Medical & Career Journey, Glioblastoma, Castleman Disease (49:10) Autoimmune Disease, Driven Personality, Stress & Immune System (52:52) Castleman Disease, Treatment, Chemotherapy (55:54) Physician Continuing Education, Santa Claus Theory of Civilization; Science Collaboration (1:03:32) Medical School, Relapse & “Overtime”, Finding a New Treatment, Rapamycin (1:12:46) Sport, Football & Resilience; Challenge & Personal Growth, Family (1:18:41) Sponsor: Function (1:20:29) Social Support; “Overtime”, Gratitude (1:23:19) Business School, Castleman Disease Treatment; Repurposing Drugs & AI (1:28:29) Drug Repurposing, POEMS Syndrome; Mitigating Risk (1:35:32) Nicotine, Compounds for Preventive Health; GLP-1 Agonists (1:40:51) Bioprospecting, Drug Development; AI, Prioritization & Novel Connections (1:46:18) Healthcare & Children; Hope, Action & Impact Circuit; Challenge & Super-Agers (1:52:50) Get Involved with Every Cure (1:56:20) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Howie and Harlan are joined by Yale School of Medicine immunologist Akiko Iwasaki, a leading authority on vaccines and long COVID. Harlan reflects on America's crisis of trust in federal agencies; Howie provides some good news about bird flu.  Links: Losing Trust Harlan Krumholz: “When Your Patient Dies” “Federal Agents Stage Raid on Canal Street in New York City, Arresting 9” “White House expands East Wing demolition as critics decry Trump overreach”“Americans' Job Ratings of Six Key U.S. Agencies Worsen” “NEJM and public health group are launching rival to CDC's MMWR publication” “South Carolina measles outbreak rises as schools with low vaccination see new cases” Akiko Iwasaki Health & Veritas Ep. 9: Dr. Akiko Iwasaki: Is Long COVID One Disease or Many? “The Long COVID Puzzle: Autoimmunity, Inflammation, and Other Possible Causes” “A New Kind of Clinical Trial: Bringing Long COVID Research Into Patients' Homes” “New Evidence Supports Autoimmunity as One of Long COVID's Underlying Drivers” “Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome” “Long Covid: A parallel pandemic” “Effectiveness of Colchicine for the Treatment of Long COVID” Akiko Iwasaki and Harlan Krumholz: “Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial” “Does Paxlovid Reduce Long COVID Symptoms? Yale-Led Trial Finds Out” Akiko Iwasaki: “Unexplained post-acute infection syndromes” “Post-Acute Infection Syndromes Will Be the Focus of New YSM Center” CDC: ME/CFS Basics “Varicella-zoster virus reactivation and the risk of dementia” Akiko Iwasaki and Harlan Krumholz: “Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination” “A small study on Covid vaccine safety sparks an online tempest” “We have ‘post-vaccination syndrome.' We are tired of being used to score anti-vax points” Health & Veritas Ep. 162: Paul Lombardo: Reckoning with the Dark History of Eugenics Health & Veritas Ep. 163: Michael Dunne: Confronting the Antibiotic Resistance Crisis Mayo Clinic: Alpha-gal syndrome Akiko Iwasaki: Woman shares what it's like to live with alpha-gal meat allergy triggered by tick bite” “‘Explosive increase' of ticks that cause meat allergy in US due to climate crisis” “Why Is Martha's Vineyard Going Vegan? It's All About Tick Bites.” “Beneficial Bloodsucking” Akiko Iwasaki on X Bird Flu “Bird Flu Is Back” CDC: H5 Bird Flu: Current Situation “RNA replicon vaccination confers long-lasting protection against H5N1 avian influenza in 23 zoo bird species” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

2025 ACC Scientific Statement on Inflammation & Cardiovascular Disease

Today Kate, Gary, Mark and Henry discuss influenza vaccines and dementia incidence, therapies for endometriosis-related pain, colchicine for secondary prevention of heart disease, and green tea and drug absorption. Links:IgNobel prizes: IgNobel Prizes were recently awarded: https://improbable.com/ig/winners/ www.ncbi.nlm.nih.gov/pubmed/40601364 https://pubmed.ncbi.nlm.nih.gov/40373315/ Colchicine for secondary prevention of CHD: https://pubmed.ncbi.nlm.nih.gov/40314334/Green tea and drug absorption: https://pubmed.ncbi.nlm.nih.gov/39748104/ https://www.sciencealert.com/a-distinct-new-form-of-diabetes-is-officially-recognizedhttps://www.medscape.com/viewarticle/malnutrition-related-diabetes-officially-named-type-5-2025a10008pd

For weight loss, complete avoidance of ultra-processed foods outperforms mere “healthy diet” comprising minimally-processed items; Research fraud undermines anti-dementia drug pipeline; Comprehensive lifestyle modification program scores against cognitive decline; Women's brains especially vulnerable to Omega-3 deficiencies; Bible says “Lame shall walk again” and 21st century science may soon bring about this miracle; Breakthroughs in rheumatoid arthritis treatment.

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared to Placebo: The Ekstrom Trial

Marcela Belleza e Raphael Coelho convidam Matheus Rezende, residente do último ano de Cardiologia - Incor, para conversar sobre manejo de doença coronariana crônica em tres tópicos:- Como realizar a investigação inicial?- Como fazer a terapia medicamentosa inicial?- O que fazer com o paciente que não melhora?Referências: 1. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes [published correction appears in Eur Heart J. 2025 Feb 21:ehaf079. doi: 10.1093/eurheartj/ehaf079.]. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae1772. Virani, Salim S et al. “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Circulation vol. 148,9 (2023): e9-e119. doi:10.1161/CIR.00000000000011683. Montone RA, Rinaldi R, Niccoli G, et al. Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions. J Am Coll Cardiol. 2024;84(8):744-760. doi:10.1016/j.jacc.2024.06.0154. Mortensen MB, Dzaye O, Steffensen FH, et al. Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis. J Am Coll Cardiol. 2020;76(24):2803-2813. doi:10.1016/j.jacc.2020.10.0215. Doenst T, Haverich A, Serruys P, et al. PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(8):964-976. doi:10.1016/j.jacc.2018.11.0536. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa19159227. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389(25):2319-2330. doi:10.1056/NEJMoa23106108. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa17091189. Howlett JG, Stebbins A, Petrie MC, et al. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. JACC Heart Fail. 2019;7(10):878-887. doi:10.1016/j.jchf.2019.04.01810. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa202137211. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516. doi:10.1056/NEJMoa07082912. Ford TJ, Stanley B, Good R, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841-2855. doi:10.1016/j.jacc.2018.09.00613. Carvalho, Tales de et al. “Brazilian Cardiovascular Rehabilitation Guideline - 2020.” “Diretriz Brasileira de Reabilitação Cardiovascular – 2020.” Arquivos brasileiros de cardiologia vol. 114,5 (2020): 943-987. doi:10.36660/abc.20200407

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

A velha conhecida da reumatologia (e também das queridas pericardites) pode estar ganhando um novo papel na cardiologia. Neste episódio do DozeCast, Mateus Prata e William Batah recebem o cardiologista e pesquisador Lucas Tramujas para uma discussão profunda sobre o uso da colchicina na doença arterial coronariana (DAC).

Colchicine

Little Miss Innocent: Passion. Poison. Prison. Kimberly. Katie. Uneducated. Opinions. Judgmental. Chiropractor. Messy. Car. Messy. Case. Anonymous. Letter. Colchicine. Email. Framing. Affair. Screenshots. Receipts. Timeline. Sister. Opinions. Supplements. One. Question. Who killed Mary Yoder?! Official Description from Hulu: Kaitlyn Conley, a 31-year-old former receptionist, claims she has been wrongfully convicted of the 2015 killing of Mary Yoder, her former boss and the mother of her ex-boyfriend Adam. Get spicy without anyone getting murdered. Check out Dipsea sexy stories! Right now, listeners of this show can get an extended 30-day free trial! Just go to DipseaStories.com/ DATEDATELINE to start your free trial! Upgrade your sleep during Boll & Branch's Annual Spring Event! For a limited time get 20% off at BollAndBranch.com/datedateline. Exclusions apply. See site for details. To advertise on this podcast please email: ad-sales@libsyn.com   Or go to:  https://advertising.libsyn.com/ADatewithDateline Learn more about your ad choices. Visit podcastchoices.com/adchoices

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States

Contributor: Aaron Lessen, MD Educational Pearls: Colchicine is most commonly used for the prevention and treatment of gout There is research investigating the anti-inflammatory and cardioprotective effects of colchicine  This drug has a narrow therapeutic index: a small margin between effective dose and toxic dose Colchicine overdoses can be unintentional or intentional and are associated with poor outcomes Phase 1: 10 - 24 hours after ingestion Patient looks well but may have mild symptoms mimicking gastroenteritis Phase 2: 24 hours - 7 days after ingestion Multiple organ dysfunction syndrome (MODS) Phase 3: recovery is usually within a few weeks of ingestion Treatment for colchicine overdose Treat early and aggressively Gastrointestinal decontamination with activated charcoal and orogastric lavage  Dialysis and ECMO for MODS treatment References Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348. PMID: 20586571. Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol. 2015;11(11):1781-94. doi: 10.1517/17425255.2015.1076391. Epub 2015 Aug 4. PMID: 26239119. Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction.

CLEAR SYNERGY (OASIS 9): A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients with Myocardial Infarction

Tapinarof trials for AD - Minoxidil kills cats - Colchicine for aphthous stomatitis - Onychopapillomas and BAP1 - Physicians compensation models: Important and overlooked - To sign up for Luke's atopic dermatitis CME activity, go to: impactedu.gathered.com/invite/4QbYEVpbzq Want to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

مسمومیت با کلشیسین

1st AHA 2024: OASIS 9 Trial

Co-STAR: Colchicine in Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial

Thank you for joining us for another episode of the Low Carb MD Podcast. Dr. Mohammed Alo is a cardiologist based out of northwest Ohio. Dr. Alo grew up in Toledo, Ohio, attended St. John's Jesuit High School and then went on to complete an Economics degree and graduated Magna Cum Laude from the University of Toledo. He worked in politics, business, computers, sales, and networking and then went to medical school in Chicago at Midwestern University's Chicago College of Osteopathic Medicine. He has a passion for teaching and travels the country giving talks on various topics. Most of his lectures focus on teaching other physicians on various cardiology topics that span a wide gamut of topics from cardiology, to health and fitness, to diet and weight loss. Dr. Alo has countless research publications and articles in scientific, peer-reviewed journals. He's had thousands of articles published in magazines in print and online. In this episode, Drs. Tro and Mohammed talk about… (01:29) Why Dr. Mohammed chose to go into medicine and become a doctor (05:10) What Drs. Tro and Mohammed agree about (11:32) The genetics of familial hypercholesterolemia patients, how these patients are treated, and the health complications they face (23:41) Lifelong lowering of lipids, atherosclerosis, preventing atherosclerosis, and when to consider using medication (33:04) CCT scans, LDL, and high LDL's association with atherosclerosis (42:05) The power of zero study and coronary artery calcium in cardiac risk assessment (45:12) Tro's LDL levels and atherosclerotic/cardiac event risk (59:09) The findings of the ACCORD trial which studied the effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus (01:08:22) Pros and cons of statins and other drugs (01:16:04) Smoking and endothelium destruction; diabetes and cardiovascular risk (01:20:50) Whether or not plaque can be reduced/reversed (01:24:20) Fish oil pills, Colchicine, and cardiac health (01:30:03) Summing up points of disagreement as well as common ground For more information, please see the links below. Thank you for listening!   Links:   Dr. Mohammed Alo: Website: https://mohammedalo.com/ YouTube: https://www.youtube.com/user/TheMohammedAlo Cholesterol TRUTHS (book): https://www.dralo.net/cholesterol   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro Instagram: https://www.instagram.com/doctortro/ SMHP Position Statement: https://journalofmetabolichealth.org/index.php/jmh/article/view/100#:~:text=The%20SMHP%20recommends%20open%20access,research%20on%20TCR%20for%20T1DM   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/ 

In this episode, Dr. Paul Ridker, a pioneer in the field of cardiovascular inflammation, joins the CardioNerds (Dr. Gurleen Kaur, Dr. Richard Ferraro, and Dr. Nidhi Patel) to discuss the evolving landscape of inflammation as a key factor in cardiovascular risk reduction. The discussion dives into the importance of biomarkers like high-sensitivity C-reactive protein (hs-CRP) in guiding treatment strategies, the insights gleaned from landmark trials like the JUPITER and CANTOS studies, and the future of targeted anti-inflammatory therapies in cardiology. Show notes were drafted by Dr. Nidhi Patel. Audio editing by CardioNerds academy intern, Grace Qiu.  This episode was produced in collaboration with the American Society of Preventive Cardiology (ASPC) with independent medical education grant support from Lexicon Pharmaceuticals. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Targeting Inflammation for Cardiovascular Risk "If you don't measure it, you can't treat it”: Incorporate hs-CRP into routine practice for patients at risk of cardiovascular events, as it provides crucial information for risk stratification and management. Recognize the dual benefits of statins in lowering both LDL and inflammation, particularly in patients with elevated hs-CRP. Encourage patients to adopt heart-healthy habits, as lifestyle changes remain foundational in reducing both cholesterol and inflammatory risk. Reminder that most autoimmune or inflammatory diseases, from psoriasis to Addison's disease to lupus to scleroderma to inflammatory bowel disease, have been shown to have elevated cardiovascular risk Ongoing randomized trials including ZEUS, HERMES, and ARTEMIS will inform whether novel targeting of IL-6 can safely lower cardiovascular event rates or slow renal progression Show notes - Targeting Inflammation for Cardiovascular Risk Why is it important to measure both LDL and hs-CRP, and what factors increase hs-CRP? Inflammation and hyperlipidemia are synergistic in promoting atherosclerosis. They interact to exacerbate plaque formation and instability, increasing the risk of cardiovascular events. Just like we measure blood pressure and LDL to know what to treat, we should measure hs-CRP to guide targeted therapy. Clinical Example: in Ms. Flame's case, despite achieving target LDL levels with statins, her elevated hs-CRP indicates ongoing inflammation and residual cardiovascular risk that should be assessed. Residual inflammatory risk should be assessed in both primary and secondary prevention. Increased BMI1, smoking2, a sedentary lifestyle3, and genetics4 (such as a higher risk of metabolic disease in South Asians) all raise hs-CRP levels. SGLTi5 and GLP-1 agonists6 have also been shown to decrease hs-CRP levels. What data do we have to support measuring hs-CRP?  Women's Health Study7: an early study showing that hs-CRP predicted risk at least as well as LDL cholesterol and that models incorporating hs-CRP in addition to lipids were significantly better at predicting risk than models based on lipids alone. JUPITER Trial8 (Primary Prevention): Among patients with normal LDL but elevated hs-CRP there was a 44% reduction in major cardiovascular events (>50% in MI and stroke) and a 20% reduction in all-cause mortality in patients treated with statins. These results led to changes in guidelines in recognizing the need to measure and treat inflammation. CANTOS Trial9 (Secondary Prevention): Randomized >10K patients with previous MI and hs-CRP ≥ 2mg/L and found that canakinumab reduced hs-CRP level from baseline in a dose-dependent manner, without reduction in the LDL, ApoB, TG, or blood pressure. What are the guidelines and supportive data on using Colchicine? 

On this episode of the Real Life Pharmacology podcast, we cover 5 more medications in the top 200. Metronidazole is an antibiotic for infection. One of the most common complaints from patients involves reporting of a metallic taste in the mouth. Levetiracetam is an anti-seizure medication. Sedation, dizziness, and other adverse effects of the central nervous system are the most common complications. Colchicine is a gout medication. The most memorable side effect associated with this medication is diarrhea. Olanzapine is an antipsychotic. Olanzapine carries a higher risk for metabolic syndrome compared to other antipsychotics. Dutasteride is a 5 alpha-reductase inhibitor that is indicated for the treatment of BPH. If you are looking for all of our study materials and Amazon books, check them out at Meded101.com/store!

In this episode of Hart2Heart with Dr. Mike Hart is joined by Dr. Anish Koka to a cardiologist based in Pennsylvania. They dive deep into a range of topics related to cardiology, focusing on cardiac health, the impacts of the C19Vax on the heart, and the potential benefits of various blood markers in assessing heart disease risk. Dr. Koka shares his knowledge on the vaccine's long-term effects, the role of statins, aspirin use, and the relevance of markers like LDL, HDL, triglycerides, and Lp(a). Additionally, they discuss how these markers influence treatment decisions in practice and explore novel approaches to cardiovascular health. Guest Bio and Links: Dr. Anish Koka is a Philadelphia-based cardiologist with a passion for patient-centered care and personalized treatment plans. He runs a private practice and frequently writes and speaks on healthcare policy and cardiac health. Listeners can learn more about Dr. Anish Koka at his website and on substack @anishkokamd  Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart    (0:15) Dr. Hart introduces Dr. Anish Koka to the listeners (0:50) Dr. Koka gives a brief introduction and background of himself  (4:00) Myocarditis and COVID-19 vaccines (6:00) No long-term rise in cardiac issues post-vaccine (9:00) Long-term cardiac complication (12:30) A closer look at triglyceride to HDL ratio (18:00) The history of LDL and its impact on heart health (22:30) The law of diminishing returns in cholesterol management (26:30) Role of CRP in cardiac risk assessment (31:00) Colchicine - a powerful anti-inflammatory drug (35:30) A possible new marker for cardiovascular risk - Lp(a) (44:00) Particle size testing - worth it? (47:30) High oxidized LDL (52:00) Aspirin - general approaches --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community.  Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

CardioNerds Cardio-Rheumatology Series Co-Chairs Dr. Rick Ferraro, Dr. Gurleen Kaur, and Episode Lead Dr. Ronaldo Correa discuss “The Role of Inflammation in Cardiovascular Disease” with Dr. Antonio Abbate. Join the CardioNerds as they kick off the Cardio-Rheumatology series with Dr. Antonio Abbate. In this episode, Dr. Abbate, a leading expert in cardio-immunology, discusses the role of inflammation in cardiovascular disease. We explore the molecular mechanisms linking inflammation to atherosclerosis, the impact of chronic low-grade systemic inflammation on heart disease, and potential therapeutic targets. Dr. Abbate shares insights on how genes and lifestyle factors contribute to inflammation, the use of inflammatory markers in clinical practice, and emerging anti-inflammatory therapies in atherosclerotic cardiovascular disease. Tune in for an enlightening conversation on the intersection of inflammation and cardiovascular health. Dr. Ronaldo Correa drafted the notes. Episode audio was engineered by Dr. Amit Goyal. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Cardio-Rheumatology: The Role of Inflammation in Cardiovascular Disease Inflammation is key in the pathogenesis and progression of atherosclerosis. Estimating systemic inflammation is part of a comprehensive preventive assessment (primary/secondary). Patients with autoimmune inflammatory diseases are at a higher risk for cardiovascular events. C-reactive protein (CRP) can estimate systemic inflammation and help assess residual inflammatory risk in patients with traditional intermediate/low cardiovascular disease, guiding management consideration with lipid-lowering therapy, aspirin, and colchicine. The pharmacological management of atherosclerosis is evolving beyond primarily lipid-lowering therapies to focus on targeting the underlying residual inflammatory process. Colchicine (inflammasome blocker as an anti-mitotic drug) is approved for use in chronic stable CVD in selected cases, and interleukin pathway blockers, especially IL-1 and IL-6, are under clinical trial investigation. First things first! Prioritize treating and optimizing traditional risk factors and comorbidities and emphasize lifestyle modifications to reduce cardiovascular disease (control diabetes and hypertension, reduce or cease smoking/alcohol, lose weight, and engage in regular physical activity). They all impact inflammation directly or indirectly Show notes - Cardio-Rheumatology: The Role of Inflammation in Cardiovascular Disease Notes: Notes drafted by Dr. Ronaldo Correa. What is the link between inflammation and cardiovascular atherosclerosis? Inflammation is involved both in the pathogenesis and progression of atherosclerosis.Histopathological coronary atherosclerosis studies have demonstrated the presence of inflammatory mediators as well as a central role of factors of innate immunity such as macrophages and T cells which can interact with vascular smooth muscle cells in the progression of atherosclerotic plaque.Patients with autoimmune inflammatory conditions have earlier and higher cardiovascular event rates (accelerated atherosclerosis due to residual inflammatory risk). Elevated inflammatory markers (for example, high CRP) predict cardiovascular events. How should inflammation be considered in the context of residual cardiovascular risk? Inflammation may be the inciting factor in atherosclerosis, or it may amplify the process driven primarily by other risk factors. Therefore, treating the comorbidities and traditional CVD contributors is key to reducing the vicious inflammatory cycle.Assessing residual risk using inflammatory markers can assist in management. C-reactive protein (CRP) can estimate systemic inflammation and help assess re...

Hello, Hello! This one is a bit longer than the usual episode, but I wanted to actually finish everything I had planned, Starting off with what was left out of last weeks episode, Colchicine. Then we dive into the wild world of anesthesia and paralytics that are known for their use during surgery/procedures but have also had a rough history recreationally and criminally. We discuss such famous cases as the deaths of Michael Jackson and Matthew Perry, as well as that of Elijah McClain, who died as a result of poisoning during an interaction with police and paramedics. I want to warn you guys that there is some talk of drug abuse, attempted suicide, and racism/racial profiling and excessive force involving police/EMS. Please feel free to let us know your thoughts as we process these cases together and learn about more poisons and their uses + effects! We are so grateful for our listeners and supporters! You guys are the best! Follow us on socials: The Poisoner's Almanac on IG- ⁠https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==⁠ Adam- ⁠https://www.tiktok.com/@studiesshow?is_from_webapp=1&sender_device=pc⁠ Becca- ⁠https://www.tiktok.com/@yobec0?is_from_webapp=1&sender_device=pc⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/goldstar002/support

Buck shares his experience visiting a cardiologist and discusses his family history of heart disease. He explains the importance of coronary calcium CT scans and the significance of calcium scores. Buck also highlights the role of lipoprotein little a (Lp(a)) in cardiovascular disease and the potential for new medications to target and lower Lp(a) levels. He explores the use of low-dose colchicine as an anti-inflammatory treatment for coronary artery disease and atrial fibrillation.

Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Non-invasive Imaging for Vulnerable Plaque   PET Imaging Finds Vulnerable Plaques That Cause MI https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2 JACC paper https://doi.org/10.1016/j.jacc.2024.03.419 Original JAMA-Card paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2806690 II. Industry Payments to Fellows JAMA Network Letter https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821267 III. GLP-1a Class Effect? Semaglutide Significantly Improves Chronic Kidney Disease https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9 Mounjaro Beats Ozempic, So Why Isn't It More Popular? https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd JAMA-Internal Medicine: Semaglutide vs Tirzepatide https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080  SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 FLOW trial https://www.nejm.org/doi/full/10.1056/NEJMoa2403347 SURPASS-CVOT – Rationale https://doi.org/10.1016/j.ahj.2023.09.007 IV. Colchicine and Trial Interpretation in the Lancet CONVINCE https://doi.org/10.1016/S0140-6736(24)00968-1 V. PFA Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed? https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

N Engl J Med 2019;381:2497-2505Background: Inflammation increases the risk of atherosclerosis, and reducing inflammation with canakinumab, a monoclonal antibody that neutralizes interleukin-1β, reduced plasma markers of inflammation and the risk of future myocardial infarctions but was associated with small yet statistically significant increased risk of fatal infections. Methotrexate, in the CIRT trial, did not reduce plasma markers of inflammation or cardiovascular events.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Colchicine, extracted from the plant autumn crocus, is a potent inexpressive anti-inflammatory medication that has been used for centuries, and is used for conditions like gout, familial Mediterranean fever and pericarditis.The Colchicine Cardiovascular Outcomes Trial (COLCOT) sought to test the hypothesis that colchicine is superior to placebo in reducing cardiovascular events in patients with recent myocardial infarction.Patients: Eligible patients were adults who had myocardial infarction within 30 days of enrollment, had any planned revascularization completed, and were on guidelines recommended treatment. Exclusion criteria included severe heart failure, left ventricular ejection fraction

In his weekly clinical update, Dr. Griffin delves into discussing drinking “raw” milk possessing H5N1 influenza virus, if the virus can reproduce in the human gut, and the meaning of finding viral RNA in wastewater samples before reviewing the recent statistics on SARS-CoV-2 infection, the guidelines for spring administration of COVID vaccines boosters, withdrawal of AstraZeneca's SARS-CoV-2 vaccine from the European market, discusses the emergency use application of a pre-exposure prophylactic, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if administration of colchicine for the management of COVID-19, compares and provides information for the enrollment into the NIH clinical trials of long COVID and its effects on sleep, exercise intolerance and the cognitive profile in multiple sclerosis and post-COVID, exercise intolerance and post-exertional malaise. For more information about cow and milk infection by H5N1 listen to the discussion with Richard Webby on TWiV 1113 and for long COVID-19 listen to TWiV 1088. Dr. Griffin also provides a list of apps for monitoring one's health including brain health. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Who demands milk infected with H5N1? (Futurism) Uncowed by milk possessing H5N1  (LA Times) Cow flu flying around for 4 months (CNN) The unpasteurized raw milk institute (Raw Milk Institute) Infection and reproduction of H5N1 in the human gut (JID) Wastewater samples identified H5N1 in 9 cities (medrxiv) Richard Webby, is H5N1 a concern? (TWiV 1113) COVID-19 national trend (CDC) COVID-19 deaths (CDC) Spring vaccineadvice (CIDRAP) Older adult spring booster available (CDC) Advisory committee for immunization practices slides (CDC) Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC) Withdrawal of Astra-Zeneca SARS-CoV-2 vaccine in Europe (European Medicines Agency) Astra-Zeneca withdraws SARS-CoV-2 vaccine from market (AP news) Global vaccine data/adverse event network (Vaccine) EUA for pemgarda (FDA) CDC Quarantine guidelines (CDC) Early phase of SARs-CoV-2 infection (COVID.gov) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (IDSociety) Overuse ofantibiotics for COVID-19: a viral disease (European Society of Clinical Microbiology and Infectious Diseases) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (IDSociety) Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio) Updated respiratory virus guidances (CDC) What do when your heathcare provider is infected with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Colchicine for managing COVID-19 (BMC Pulmonary Medicine) Colchicine guidelines (ID Society) Long COVID evidence based review TWiV shout out (TWiV 1088) NIH long COVID sleep disturbance, exercise intolerance and post exertional malaise clinical trials (NIH News) COVID-19 Yorkshire rehabilitation scale (BML Open Respiratory Research) Visible heart monitor (Makevisible) Bearable app (Bearable) Tracking your chronic illness using Flaredown (Flaredown) Improving your brain health (BrainHQ)Vanderbilt's long COVID resources: podcasts and books (Vanderbilt University) Contribute to our Floating Doctors fundraiser Letters read on TWiV 1114 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-379 Overview: Recent data has shown that colchicine can improve outcomes in patients with known coronary artery disease (CAD), with consideration of colchicine now recommended by the American Heart Association (AHA). Hear valuable insights into the potential benefits and limitations to refine your clinical approach to managing CAD. Episode resource links: Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847.  Mohammadnia N, Los J, Opstal TSJ, et al. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial. Front Cardiovasc Med. 2023;10:1244529. Published 2023 Oct 6.  Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. Published online January 5, 2024.  Guest: Alan M. Ehrlich, MD, FAAFP   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-379 Overview: Recent data has shown that colchicine can improve outcomes in patients with known coronary artery disease (CAD), with consideration of colchicine now recommended by the American Heart Association (AHA). Hear valuable insights into the potential benefits and limitations to refine your clinical approach to managing CAD. Episode resource links: Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847.  Mohammadnia N, Los J, Opstal TSJ, et al. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial. Front Cardiovasc Med. 2023;10:1244529. Published 2023 Oct 6.  Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. Published online January 5, 2024.  Guest: Alan M. Ehrlich, MD, FAAFP   Music Credit: Richard Onorato

The mysteries of inflammation: deciphering how the flames of inflammation can both heal wounds and incite a series of events leading to cardiovascular diseases. Prepare to be enlightened as we explore the dual nature of this biological response and the groundbreaking research aimed at harnessing its power for our well-being.In a conversation with Kevin Geddings and Dr. Michael Koren, we tackle the promising frontiers of treating vascular inflammation and how repurposed medications, like Colchicine, are showing surprising benefits for heart health. Delving into the interconnected world of immune system diseases such as lupus and rheumatoid arthritis, we uncover the strategic approaches in clinical trials that could revolutionize the management of these conditions. For anyone touched by cardiovascular concerns or simply fascinated by medical innovation, this episode offers a glimpse into the evolving battle against pervasive health challenges.Recording Date: April 15, 2024Be a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

If you learned that radiologists looking at CT scans for the traditional signs of coronary artery disease catch only 20 percent of the people who actually have a high risk of a heart attack, and if you learned that there's a new AI-based test that can catch subtle signs of inflammation in the other 80 percent of patients—well, you'd probably want to get that test yourself, right? Harry's guests this week, Frank Cheng and Keith Channon, are from a UK-based company that has developed just such a test. Cheng is the company's CEO, and Channon is co-founder and chief medical officer. And under their leadership, Caristo has introduced a test called CariHeart that applies machine learning to the data in a three-dimensional CT scan of the heart. It looks for otherwise invisible signs of inflammation in the fat tissue around the major coronary arteries, and then it predicts the chances that the patient will suffer a heart attack in the next eight years. Doctors can use that information to decide whether a patient needs to take a cholesterol-lowering drug like a statin or an anti-inflammatory drug like colchicine. Caristo's test is being used on an experimental basis in the UK, and it hasn't yet been approved for use in the US. But it's a leading example of the way AI, put together with fundamental advances in our understanding of human biology, is really beginning to change the practice of medicine. Cheng and Channon say Caristo's test isn't intended to put cardiologists or radiologists out of work—it's designed to help them be more effective. And given that cardiovascular disease is the number one cause of death around the world, any technology that can help catch signs of coronary artery disease earlier could save a lot of lives.For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast Please rate and review The Harry Glorikian Show on Apple Podcasts or Spotify! Here's how to do that on Apple Podcasts:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.On Spotify, the process is similar. Open the Spotify app, navigate to The Harry Glorikian Show, tap the three dots, then tap "Rate Show." Thanks!

This episode is sponsored by Farewell Coffee Roasters. Add BSFREEMD15 to your cart for 15% off your first order. Your first cup awaits! May and Tim start the episode with Tim sharing his skiing adventures in Utah while May paints at home. They discuss Tim's purchase of retro goggles and hats and humorously reference bringing back more wives as a business expense. They introduce the topic of wacky cold weather in Florida and its effects on people and animals. Tim presents a disturbing news story about a former Mayo Clinic doctor accused of fatally poisoning his wife with Colchicine. They discuss the suspicious circumstances surrounding the case and highlight the doctor's background in pharmacology and poison control. May teases their cocktail of the week and mentions upcoming shows. They delve into the effects of cold weather on Floridians, including myths and unusual animal behavior. Tim shares a fascinating story about alligators in brumation and how they adapt to freezing temperatures, while May talks about iguanas falling from trees due to the cold. Looking for something specific? Here you go! 00:00:00 - Introduction and Theme Discussion 00:03:15 - Cold Snap in Florida 00:05:30 - Unusual Weather Events in Florida History 00:08:00 - How Floridians React to Cold Weather 00:09:45 - List of Common Winter Gear in Florida 00:11:00 - Listener Mail and Comments 00:12:30 - Cocktail of the Week 00:14:00 - Cold Weather Myths and Survival Tips 00:15:30 - Animal Behavior in Cold Weather 00:17:00 - Tim's Personal Encounter with a Frozen Alligator 00:18:30 - May's Iguana Rescue Mission 00:20:00 - Wildlife Conservation and Cold Weather Research 00:21:30 - Tim and May's Favorite Winter Activities 00:23:00 - Listener Suggestions and Episode Teasers Our Advice! Everything in this podcast is for educational purposes only. It does not constitute the practice of medicine and we are not providing medical advice. No Physician-patient relationship is formed and anything discussed in this podcast does not represent the views of our employers.  The Fine Print! All opinions expressed by the hosts or  guests in this episode are solely their opinion and are not to be used as specific medical advice.  The hosts,  May and Tim Hindmarsh MD, BS Free MD LLC, or any affiliates thereof are not under any obligation to update or correct any information provided in this episode. The guest's statements and opinions are subject to change without notice. Thanks for joining us! You are the reason we are here.  If you have questions, reach out to us at doc@bsfreemd.com or find Tim and I on Facebook and IG. Please check out our every growing website as well at  bsfreemd.com (no www) GET SOCIAL WITH US! www.withkoji.com/@bsfreemd

Betty and Conner Bowman have a lot in common when they marry.  Betty Bowman  graduates from the University of Kansas School of Pharmacy with a Pharmaceutical Doctorate. Her works as a hospital pharmacist while Connor Bowman gets his Internal Medicine Residency. Betty Bowman takes a position at the Mayo Clinic, so when she falls ill suddenly, the Mayo Clinic is the logical place for treatment.  It seems Betty Bowman is suffering from food poisoning, having gastrointestinal distress and dehydration. Her condition doesn't get any better.  She takes a turn for the worse, with heart problems, fluid buildup in her lungs and then part of her colon was removed, after doctors discover necrotic tissue. Bowman dies from organ failure. Then the Southeast Minnesota Medical Examiner's Office alerts the Rochester Police Department to the suspicious nature of Betty Bowman's death. The Medical Examiner's office had to halt a cremation order.   According to court records, the Medical Examiner's Office received a call from CGK- a female friend of the Bowman's who said Betty and Connor Bowman were having marital issues and were talking about divorce following infidelity and a deteriorating relationship. In the Criminal Complaint it is stated that Conner Bowman told the Medical Examiner's Office that his wife should be cremated immediately, arguing that Betty Bowman did not want to be a cadaver.  Connor Bowman also begin asking one of the medical examiner investigators if the toxicology analysis being completed would be more thorough than the analysis typically done at the hospital. Bowman wanted a list of what was specifically going to be tested for. Friends of Betty Bowman began reaching out to investigators. An adult female friend of Betty Bowman told  the Rochester Police Department that she had texted with Betty Bowman  and that Bowman told her she was sick.   The friend told the detective that Betty Bowman was normally a healthy person. Another friend said a text from Betty Bowman said she thought a smoothie she had the night before might have caused her illness. Detectives began looking at all options and found husband Connor Bowman had  accessed Betty Bowman's patient account using his hospital credentials. From there he was able to locate internet searches conducted by Connor Bowman, a  Poison Specialist.    Connor Bowman was researching COLCHICINE,  a drug used to treat gout.  What's more he was  searches for information in determining what a lethal dose would be,  by entering his wife's weight.  Joining Nancy Grace Today: Dale Carson - High Profile Criminal Defense Attorney (Jacksonville), Former FBI Agent, Former Police Officer (Miami-Dade County), Author: "Arrest-Proof Yourself”, DaleCarsonLaw.com, Twitter: @DaleCarsonLaw  Caryn L. Stark - Psychologist, renowned TV and Radio trauma expert and consultant, www.carynstark.com, Instagram: carynpsych, FB: Caryn Stark Private Practice   Robin Dreeke - Behavior Expert & former FBI Special Agent / Chief of the FBI Counterintelligence Behavioral Analysis Program, Author: "Sizing People Up: A Veteran FBI Agents Manual for Behavior Prediction", peopleformula.com, Twitter: @rdreeke   Dr. Lyle D. Burgoon, Ph.D - Toxicology expert, President and CEO of Raptor Pharm & Tox, Ltd., Fellow of the Academy of Toxicological Sciences, Critical Science Podcast: https://critscipod.com, https://toxictruthblog.com, Twitter/X: @DataSciBurgoon   Charles Kelley - Reporter & Weekend Anchor for KTTC News, kttc.com, IG & TikTok: @charliemkelley, FB: Charles Kelley KTTC   See omnystudio.com/listener for privacy information.

Starting HF meds during hospitalization for HF, Impella, testosterone, and colchicine are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Starting HF Meds During Hospitalization for HF Starting Indicated Heart Failure Meds In-Hospital: Progress, Opportunities https://www.medscape.com/viewarticle/993539 - Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction https://www.jacc.org/doi/full/10.1016/j.jchf.2023.04.015 II. Impella - Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock https://jamanetwork.com/journals/jamacardiology/fullarticle/2806562 - Evidence Generation for Novel Cardiovascular Devices—Putting the Horse Back in Front of the Cart https://jamanetwork.com/journals/jamacardiology/fullarticle/2806565 III. Testosterone Big Trial Reassures on Heart Safety of Testosterone in Men https://www.medscape.com/viewarticle/993322 - Cardiovascular Safety of Testosterone-Replacement Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa2215025 IV. Colchicine for CV Disease Low-Dose Colchicine Approved for CVD: Now What? https://www.medscape.com/viewarticle/993578 - Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction https://www.nejm.org/doi/full/10.1056/nejmoa1912388 - Colchicine in Patients with Chronic Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa2021372 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net